(Q42996802)

12 November 2017

title

Hepatic and renal safety profile of tenofovir in HIV-infected patients with hepatitis C, including patients on interferon plus ribavirin (English)

1 reference

12 November 2017

1 reference

1 reference

5

Vincent Soriano

1 reference

12 November 2017

author name string

Matilde Sánchez-Conde

1

1 reference

12 November 2017

Paloma Gil

2

1 reference

12 November 2017

Mar Sánchez-Somolinos

3

1 reference

12 November 2017

Juan Gonzalez-Lahoz

4

1 reference

12 November 2017

publication date

1 September 2005

1 reference

12 November 2017

1 reference

12 November 2017

volume

6

1 reference

12 November 2017

issue

5

1 reference

12 November 2017

page(s)

278-280

1 reference

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1310%2FFRWE-HCGF-K3BG-DG8P

Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFRWE-HCGF-K3BG-DG8P

Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFRWE-HCGF-K3BG-DG8P

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFRWE-HCGF-K3BG-DG8P

Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFRWE-HCGF-K3BG-DG8P

Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFRWE-HCGF-K3BG-DG8P

Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFRWE-HCGF-K3BG-DG8P

Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFRWE-HCGF-K3BG-DG8P

Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFRWE-HCGF-K3BG-DG8P

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFRWE-HCGF-K3BG-DG8P

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFRWE-HCGF-K3BG-DG8P

Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFRWE-HCGF-K3BG-DG8P

Fanconi syndrome and renal failure induced by tenofovir: a first case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FFRWE-HCGF-K3BG-DG8P

10.1310/FRWE-HCGF-K3BG-DG8P

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference